S&P 500 Futures
(0.30%) 5 311.25 points
Dow Jones Futures
(0.27%) 38 897 points
Nasdaq Futures
(0.41%) 18 667 points
Oil
(-0.19%) $76.84
Gas
(3.75%) $2.68
Gold
(-0.27%) $2 339.50
Silver
(-0.59%) $30.26
Platinum
(-0.05%) $1 041.50
USD/EUR
(-0.04%) $0.921
USD/NOK
(-0.01%) $10.48
USD/GBP
(0.02%) $0.785
USD/RUB
(-0.35%) $90.11

Realtime updates for Immunovant Inc [IMVT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
53.33%
return 0.59%
SELL
42.86%
return 2.13%
Last Updated31 May 2024 @ 16:00

-3.86% $ 25.39

SELL 130279 min ago

@ $35.47

Issued: 4 Mar 2024 @ 14:39


Return: -28.42%


Previous signal: Mar 1 - 13:21


Previous signal: Buy


Return: -1.61 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia...

Stats
Today's Volume 2.77M
Average Volume 1.19M
Market Cap 3.71B
EPS $0 ( 2024-05-27 )
Next earnings date ( $-0.480 ) 2024-08-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -13.51
ATR14 $0.0550 (0.22%)
Insider Trading
Date Person Action Amount type
2024-05-22 Barnett Eva Renee Sell 4 042 Common Stock
2024-05-22 Salzmann Peter Sell 16 163 Common Stock
2024-05-22 Butchko Julia G. Sell 3 247 Common Stock
2024-05-22 Macias William L. Sell 3 247 Common Stock
2024-05-22 Levine Mark S. Sell 3 242 Common Stock
INSIDER POWER
85.51
Last 100 transactions
Buy: 7 337 754 | Sell: 515 313

Volume Correlation

Long: 0.11 (neutral)
Short: 0.46 (neutral)
Signal:(69.516) Neutral

Immunovant Inc Correlation

10 Most Positive Correlations
LPSN0.953
FWRD0.95
FLGT0.95
SSTI0.946
NARI0.946
AMPH0.946
COMM0.942
BNRG0.942
RIVN0.939
ASLE0.939
10 Most Negative Correlations
ESTA-0.939
KINS-0.938
ARYD-0.922
JVA-0.921
DXJS-0.921
NTRA-0.921
WING-0.918
PNTG-0.918
APXI-0.916
SWAV-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immunovant Inc Correlation - Currency/Commodity

The country flag -0.37
( neutral )
The country flag -0.30
( neutral )
The country flag 0.00
( neutral )
The country flag -0.04
( neutral )
The country flag -0.01
( neutral )

Immunovant Inc Financials

Annual 2024
Revenue: $0
Gross Profit: $-231 000 (0.00 %)
EPS: $-1.880
FY 2024
Revenue: $0
Gross Profit: $-231 000 (0.00 %)
EPS: $-1.880
FY 2023
Revenue: $0
Gross Profit: $-1.32M (0.00 %)
EPS: $-1.710
FY 2022
Revenue: $0
Gross Profit: $-1.23M (0.00 %)
EPS: $-1.430

Financial Reports:

No articles found.

Immunovant Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Immunovant Inc

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 1.5462260246277 seconds
Number of API calls: 2
Number of DB calls: 8